adamantane has been researched along with Body Weight in 80 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.75) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 26 (32.50) | 29.6817 |
| 2010's | 48 (60.00) | 24.3611 |
| 2020's | 3 (3.75) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CT; Chen, CY; Chiu, TY; Huang, YW; Juang, JH; Kao, CW | 1 |
| Dronamraju, N; Ekholm, E; Garcia-Sanchez, R; Jabbour, SA; Johnsson, E; Lind, M; Vilsbøll, T | 1 |
| Li, M; Song, J; Ying, M; Zhuang, Y | 1 |
| Attia, A; El-Shenawy, S; Gomaa, N; Hassan, A; Hegazy, R; Kenawy, S; Zaki, H | 1 |
| Azuma, K; Goto, H; Ikeda, F; Kanazawa, A; Komiya, K; Masuyama, A; Mita, T; Ogihara, T; Ohmura, C; Osonoi, T; Osonoi, Y; Saito, M; Sato, J; Shimizu, T; Someya, Y; Suzuki, L; Takayanagi, N; Takeno, K; Uzawa, H; Watada, H | 1 |
| Ahn, SK; Chang, KH; Han, D; Hong, SP | 1 |
| Chen, H; Garcia-Sanchez, R; Mathieu, C; Rosenstock, J; Saraiva, GL | 1 |
| Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L | 1 |
| García-Sánchez, R; Jacob, S; Johnsson, E; Perl, S; Rosenstock, J | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H | 2 |
| Araújo, GR; Ávila, Dde L; Costa, DC; de Lima, WG; Diniz, MF; Miranda, PH; Pedrosa, ML; Silva, M; Silva, ME | 1 |
| Dengler, TJ; Doesch, AO; Ehlermann, P; Erbel, C; Frankenstein, L; Gleißner, C; Gueler, I; Helmschrott, M; Katus, HA; Mueller, S; Oeing, CU; Ruhparwar, A | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Scheen, AJ | 1 |
| Ishibashi, Y; Maeda, S; Matsui, T; Nakashima, S; Nishino, Y; Ojima, A; Yamagishi, S; Yamakawa, R; Yoshida, Y | 1 |
| Aleksandrov, AA; Chernova, TO; Dedov, II; Il'in, AV; Shestakova, MV; Shmushkovich, IA; Suhareva, OIu | 1 |
| Araga, M; Del Prato, S; Kothny, W; Lukashevich, V | 1 |
| Brook, D; Fisher, SA; Kalra, S; Montanaro, M; Monyak, J; Moses, RG; Sockler, J; Visvanathan, J | 1 |
| Boyd, S; deSchoolmeester, J; Dossetter, AG; Goldberg, FW; Groombridge, SD; Gutierrez, PM; Kemmitt, PD; Robb, GR; Scott, JS; Sjögren, T; Swales, JG; Turnbull, AV; Wild, MJ | 1 |
| Andrzejak, V; Barczyk, A; Body-Malapel, M; Chavatte, P; Desreumaux, P; Djouina, M; Leleu-Chavain, N; Millet, R; Rigo, B; Tourteau, A | 1 |
| Ding, M; Li, CJ; Liu, XJ; Yu, DM; Yu, P; Yu, Q; Zhang, QM | 1 |
| Avogaro, A; Dardano, A; de Kreutzenberg, SV; Del Prato, S | 1 |
| Abdallah, K; Hassanein, M; Schweizer, A | 1 |
| Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP | 1 |
| Bryzinski, B; Cook, W; Hirshberg, B; Minervini, G | 1 |
| Bader, G; Blüher, M; Foley, JE; Schweizer, A | 1 |
| Abdallah, DM; Al-Shorbagy, MY; Arab, HH; Nassar, NN | 1 |
| Abou Jaoude, E; Al-Arouj, M; DiTommaso, S; Fawwad, A; Latif, ZA; Orabi, A; Rosales, R; Shah, P; Vaz, J | 1 |
| Gandin, V; Giorgetti, M; Marzano, C; Porchia, M; Tisato, F; Trenti, A; Trevisi, L; Zanusso, I | 1 |
| Sugita, M | 1 |
| Choi, CS; Han, HY; Jeong, KH; Jun, HS; Kim, S; Kim, SS; Lee, HJ; Oh, H; Ryu, JH; Sa, JH; Son, HJ | 1 |
| El Batch, MM; El Batsh, MM; Shafik, NM; Younos, IH | 1 |
| Chen, H; Garcia-Sanchez, R; González González, JG; Hansen, L; Herrera Marmolejo, M; Iqbal, N; Johnsson, E; Mathieu, C | 1 |
| Aggarwal, N; Chen, H; Chin, A; Garcia-Hernandez, P; Hansen, L; Iqbal, N; Johnsson, E; Matthaei, S | 1 |
| Feng, B; Li, P; Tang, Z; Wang, L; Yan, X | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Khamseekaew, J; Pintana, H; Siri-Angkul, N; Tanajak, P | 1 |
| Davidson, JA; Gross, JL; Parente, EB | 1 |
| Dejager, S; Foley, J; Halimi, S; Minic, B; Schweizer, A | 1 |
| Ahrén, B; Byiers, S; Dejager, S; Ferrannini, E; Fonseca, V; Matthews, D; Shao, Q; Zinman, B | 1 |
| Barnett, AH; Piya, MK; Tahrani, AA | 1 |
| Mikhail, N | 2 |
| Maldonado-Lutomirsky, M; Niggli, M; Rosenstock, J | 1 |
| Bosi, E; Dejager, S; Schweizer, A | 1 |
| Bolli, G; Colin, L; Dotta, F; Goodman, M; Minic, B | 1 |
| Baek, HS; Jin, HY; Liu, WJ; Park, JH; Park, TS | 1 |
| Fitzpatrick, LR; Green, CL; Maines, LW; Smith, CD; Zhuang, Y | 1 |
| Bilo, HJ; Goudswaard, AN; Houweling, ST; Kleefstra, N; Kooy, A; van Hateren, KJ; Verhoeven, S | 1 |
| Ciccarelli, L; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Mereu, R; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA | 1 |
| Clar, C; Cummins, E; Marien, M; Philip, S; Richter, B; Royle, P; Waugh, N | 1 |
| Ahren, B; Couturier, A; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, V; Matthews, DR; Zinman, B | 1 |
| Foley, JE; Jordan, J | 1 |
| Donahue, H; Fitzpatrick, LR; Frauenhoffer, EE; French, KJ; Green, C; Maines, LW; Mosher, TJ; Paul, E; Smith, CD; Upson, JJ; Zhuang, Y | 1 |
| Aerts, JM; Bijl, N; Bijland, S; Groen, AK; Houben-Weerts, JH; Houten, SM; Langeveld, M; Ottenhoff, R; Romijn, JA; van den Berg, SA; van Dijk, KW; van Roomen, CP; Voshol, PJ | 1 |
| Bianchi, R; Burkey, B; Cavaletti, G; Cervellini, I; Ghezzi, P; Lauria, G; Oggioni, N; Porretta-Serapiglia, C | 1 |
| Jin, HY; Kim, W; Liu, WJ; Liu, YN; Park, SK; Park, TS; Shao, YM; Xie, SH | 1 |
| Cheetham, S; Francis, J; Kirby, M; Poucher, SM; Vickers, SP; Zinker, B | 1 |
| Foley, J; Gallwitz, B; Kothny, W; Kozlovski, P; Lukashevich, V; Shao, Q | 1 |
| Dickinson, S; Foley, JE; Groop, PH; Kothny, W; Lukashevich, V; Schweizer, A | 1 |
| Dhakad, PK; Joshi, M; Joshi, S; Kanawat, DS; Kurmi, MK; Mishra, A; Raikwar, SK; Sharma, AK; Sharma, P; Srinivasan, BP; Srivastava, V | 1 |
| Ahrén, B; Holmes, D; Jansson, PA; Landin-Olsson, M; Schweizer, A; Svensson, M | 1 |
| Aerts, JM; Boon, L; Bullens, D; Ceuppens, JL; Geboes, K; Kasran, A; Maerten, P; Rutgeerts, P; Shen, C; Van Assche, G | 1 |
| Ahrén, B; Burkey, B; Hughes, TE; Sörhede Winzell, M | 1 |
| Edelman, SV | 1 |
| Golozoubova, V; Gotfredsen, CF; Knudsen, LB; Raun, K; Rolin, B; von Voss, P | 1 |
| Baron, MA; Dejager, S; Garber, AJ; Rochotte, E; Schweizer, A | 1 |
| Baron, MA; Camisasca, RP; Couturier, A; Cressier, F; Dejager, S; Kim, SW; Rosenstock, J | 1 |
| Dejager, S; Foley, JE; Razac, S; Schweizer, A | 1 |
| Bansal, VS; Davis, JA; Dhar, A; Khanna, V; Mahajan, DC; Mittra, S; Priyadarsiny, P; Roy, S; Saini, KS; Sattigeri, J; Singh, S | 1 |
| Balez, S; Campestrini, J; He, YL; Howard, D; Laurent, A; Ligueros-Saylan, M; Sabo, R; Sadler, BM; Wang, Y | 1 |
| Bolli, G; Cohen, SE; Dotta, F; Rochotte, E | 1 |
| Ahrén, B | 2 |
| Cai, JX; Zhang, M | 1 |
| Banerji, MA; Baron, MA; Camisasca, RP; Couturier, A; Ebeling, P; Foley, JE; Garber, AJ; Gudbjörnsdottir, S | 1 |
| Dunning, BE; Foley, JE; Lalanne, G; Mari, A; Nilsson, PM; Scherbaum, WA; Schweizer, A; Wang, Y | 1 |
| Carfagnini, JC; Rehbinder, C; Rönnbäck, C | 1 |
| Arensman, JB; Hilmas, DE; Tschorn, RR | 1 |
| Nilsson, A; Ousavaplangchai, L; Rehbinder, C; Rönnbäck, C | 1 |
16 review(s) available for adamantane and Body Weight
| Article | Year |
|---|---|
Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Topics: Adamantane; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular System; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Lipids; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes.
Topics: Adamantane; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Glycated Hemoglobin; Humans; Hypoglycemia; Nitriles; Practice Guidelines as Topic; Pyrrolidines; Quality of Life; Vildagliptin | 2015 |
Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Fasting; Female; Humans; Linear Models; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vildagliptin; Weight Gain; Weight Loss | 2014 |
Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Postprandial Period; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Combinations; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Metformin; Nitriles; Pyrrolidines; Tablets; Treatment Outcome; Vildagliptin | 2008 |
Drug evaluation: vildagliptin-metformin single-tablet combination.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Lipids; Metformin; Nitriles; Practice Guidelines as Topic; Pyrrolidines; Safety; Treatment Outcome; Vildagliptin | 2009 |
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Topics: Adamantane; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2010 |
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Topics: Adamantane; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Nitriles; Peptides; Pyrazines; Pyrrolidines; Quality of Life; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; State Medicine; Thiazolidinediones; Triazoles; United Kingdom; Venoms; Vildagliptin | 2010 |
Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Nitriles; Pyrrolidines; Vildagliptin; Weight Gain | 2010 |
Incretins: what does the future hold?
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Exenatide; Glucagon-Like Peptide 1; Humans; Liraglutide; Nitriles; Peptides; Protease Inhibitors; Pyrrolidines; Venoms; Vildagliptin | 2005 |
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Hypoglycemic Agents; Incretins; Islets of Langerhans; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Topics: Adamantane; Body Weight; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nausea; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Vomiting | 2008 |
28 trial(s) available for adamantane and Body Weight
| Article | Year |
|---|---|
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Treatment Outcome | 2020 |
Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2017 |
Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Sulfonylurea Compounds; Weight Gain | 2019 |
Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2019 |
[A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition].
Topics: Absorptiometry, Photon; Adamantane; Blood Glucose; Body Composition; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; Waist Circumference | 2013 |
Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2014 |
A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Topics: Adamantane; Adult; Australia; Blood Glucose; Body Mass Index; Body Weight; Canada; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; India; Korea; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thailand; Treatment Outcome; United Kingdom | 2014 |
Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
Topics: Adamantane; Adult; Asian People; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
Topics: Adamantane; Asia; Biomarkers; Blood Glucose; Body Weight; Counseling; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Europe; Fasting; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Medication Adherence; Middle Aged; Middle East; Nitriles; Office Visits; Pyrrolidines; Religion and Medicine; Telephone; Time Factors; Treatment Outcome; Vildagliptin | 2014 |
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fasting; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Metformin; Risk Factors | 2014 |
Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2016 |
One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2016 |
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Time Factors; Vildagliptin | 2009 |
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Topics: Adamantane; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin; Weight Gain; Young Adult | 2009 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Vildagliptin | 2010 |
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
Topics: Adamantane; Adolescent; Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; Weight Gain; Young Adult | 2010 |
Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Asia; Australia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; United States; Vildagliptin | 2013 |
Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Body Weight; Chi-Square Distribution; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Kidney; Male; Middle Aged; Nitriles; Pyrrolidines; Severity of Illness Index; Time Factors; Treatment Outcome; Vildagliptin | 2013 |
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Circadian Rhythm; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Eating; Enzyme Inhibitors; Female; Glucagon; Glycated Hemoglobin; Humans; Insulin; Lipids; Male; Middle Aged; Pyrrolidines | 2004 |
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Ligands; Lipids; Male; Middle Aged; Nitriles; Pioglitazone; Proinsulin; Protease Inhibitors; Pyrrolidines; Thiazolidinediones; Treatment Failure; Treatment Outcome; Vildagliptin | 2007 |
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Nitriles; Pioglitazone; Protease Inhibitors; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin | 2007 |
Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Fasting; Female; Glycated Hemoglobin; Hemoglobins; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Nitriles; Placebos; Pyrrolidines; Time Factors; Treatment Outcome; Vildagliptin | 2007 |
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
Topics: Adamantane; Administration, Oral; Adolescent; Adult; Algorithms; Analysis of Variance; Area Under Curve; Biological Availability; Body Mass Index; Body Weight; Cross-Over Studies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Half-Life; Humans; Hypoglycemic Agents; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Nitriles; Pyrrolidines; Sex Factors; Vildagliptin | 2007 |
Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Treatment Outcome; Vildagliptin | 2008 |
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2008 |
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia.
Topics: Adamantane; Adult; Analysis of Variance; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Insulin; Lipids; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Time Factors; Vildagliptin | 2008 |
36 other study(ies) available for adamantane and Body Weight
| Article | Year |
|---|---|
Implanted islet mass influences the effects of dipeptidyl peptidase-IV inhibitor LAF237 on transplantation outcomes in diabetic mice.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Humans; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Pyrrolidines | 2021 |
Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin.
Topics: Adamantane; Aging; Animals; Biomarkers; Body Weight; Brain; Dementia; Dipeptides; Galactose; Glycated Hemoglobin; Hypoglycemic Agents; Insulin Resistance; Locomotion; Male; Metformin; Nerve Tissue Proteins; Oxidative Stress; Rats; Rats, Wistar; Reaction Time | 2017 |
A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adamantane; Animals; Body Weight; Enzyme Inhibitors; Humans; Mice; Models, Molecular; Protein Conformation; Rats | 2018 |
Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
Topics: Adamantane; Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiotonic Agents; Cholesterol; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Heart; Heart Rate; Insulin; Insulin Resistance; Male; Malondialdehyde; Membrane Potential, Mitochondrial; Mitochondria, Heart; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats, Wistar; Reactive Oxygen Species; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
Topics: Adamantane; Animals; Antioxidants; Biomarkers; Blood Glucose; Body Weight; Catalase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Incretins; Insulin; Insulin-Secreting Cells; Nitriles; Oxidation-Reduction; Oxidative Stress; Pyrrolidines; Rats; Streptozocin; Superoxide Dismutase; Vildagliptin | 2013 |
Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Heart Transplantation; Humans; Immunosuppressive Agents; Lipids; Male; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Vildagliptin | 2013 |
Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats.
Topics: Adamantane; Administration, Oral; Analysis of Variance; Animals; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression Profiling; Male; Nitriles; Obesity; Pyrrolidines; Rats; Real-Time Polymerase Chain Reaction; Retina; Vildagliptin | 2013 |
Optimization of brain penetrant 11β-hydroxysteroid dehydrogenase type I inhibitors and in vivo testing in diet-induced obese mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Animals; Blood Glucose; Body Weight; Brain; Crystallography, X-Ray; Cyclopropanes; Diabetes Mellitus, Type 2; Dietary Fats; Humans; Hypoglycemic Agents; Insulin; Isoenzymes; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Obese; Models, Molecular; Pyrazoles; Rats; Stereoisomerism; Structure-Activity Relationship; Thiazoles | 2014 |
Switching cannabinoid response from CB(2) agonists to FAAH inhibitors.
Topics: Adamantane; Amidohydrolases; Animals; Anti-Inflammatory Agents; Body Weight; Cannabinoids; Colitis; Disease Models, Animal; Enzyme Inhibitors; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Protein Binding; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2014 |
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2014 |
Saxagliptin: a novel antiparkinsonian approach.
Topics: Adamantane; Animals; Antiparkinson Agents; Body Weight; Brain; Cathepsin C; Cyclic AMP; Dipeptides; Disease Models, Animal; Dopamine; Drug Evaluation, Preclinical; Gene Expression Regulation; Insecticides; Lipid Peroxidation; Male; Nerve Tissue Proteins; NF-E2-Related Factor 2; Parkinson Disease; Rats; Rats, Wistar; Rotenone; Tyrosine 3-Monooxygenase | 2015 |
Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study.
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Treatment Outcome; Vildagliptin | 2015 |
Homoleptic phosphino copper(I) complexes with in vitro and in vivo dual cytotoxic and anti-angiogenic activity.
Topics: Adamantane; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Cell Proliferation; Coordination Complexes; Copper; Female; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Organophosphorus Compounds; Phosphines | 2015 |
[The perception gap between clinical trials and clinical practice].
Topics: Adamantane; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Diabetes Mellitus; Humans; Male; Nitriles; Olanzapine; Pyrrolidines; Schizophrenia; Vildagliptin | 2015 |
A potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, SKI2852, ameliorates metabolic syndrome in diabetic mice models.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Adipose Tissue; Animals; Body Weight; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Glycated Hemoglobin; Insulin Resistance; Lipids; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Pyrimidines | 2015 |
Favorable effects of vildagliptin on metabolic and cognitive dysfunctions in streptozotocin-induced diabetic rats.
Topics: Adamantane; Animals; Behavior, Animal; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Cognition; Diabetes Mellitus, Experimental; Male; Neuroprotective Agents; Nitriles; Oxidative Stress; Pyrrolidines; Rats; Rats, Sprague-Dawley; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Vildagliptin | 2015 |
Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dipeptides; DNA, Bacterial; Eating; Feces; Gastrointestinal Microbiome; Gene Expression; Glucagon-Like Peptide-1 Receptor; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; RNA, Ribosomal, 16S; Streptozocin | 2016 |
Vildagliptin and caloric restriction for cardioprotection in pre-diabetic rats.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Caloric Restriction; Cardiotonic Agents; Diet, High-Fat; Fibroblast Growth Factors; Heart Rate; Insulin Resistance; Intra-Abdominal Fat; Male; Mitochondria, Heart; Nitriles; Oxidative Stress; Prediabetic State; Pyrrolidines; Rats; Rats, Wistar; Ventricular Function, Left; Vildagliptin | 2017 |
Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Nitriles; Pyrrolidines; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vildagliptin; Weight Gain | 2009 |
Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Eating; Electric Stimulation; Epidermis; Glucagon-Like Peptide 1; Humans; Insulin; Male; Nerve Degeneration; Nitriles; Peripheral Nerves; Pyrrolidines; Random Allocation; Rats; Rats, Sprague-Dawley; Ubiquitin Thiolesterase; Vildagliptin | 2009 |
Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease.
Topics: Adamantane; Aminosalicylic Acids; Animals; Body Weight; Colon; Crohn Disease; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Epithelial Cells; Female; Gastrointestinal Agents; Humans; Interleukin-1beta; Leukocytes; Male; Mice; Mice, Inbred C57BL; Neutrophils; Peroxidase; Phosphotransferases (Alcohol Group Acceptor); Prednisolone; Pyridines; Rats; Rats, Sprague-Dawley; Treatment Outcome; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha | 2010 |
Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase.
Topics: Adamantane; Administration, Oral; Animals; Ankle; Ankle Joint; Arthritis, Experimental; Body Weight; Drug Therapy, Combination; Edema; Enzyme Inhibitors; Female; Foot; Indomethacin; Inflammation; Methotrexate; Mice; Mice, Inbred DBA; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Rats; Rats, Inbred Lew; Splenomegaly; X-Ray Microtomography | 2011 |
Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation.
Topics: 1-Deoxynojirimycin; Adamantane; Adipose Tissue; Animals; Body Weight; Carbohydrate Metabolism; Carnitine O-Palmitoyltransferase; Eating; Ghrelin; Glucose; Imino Sugars; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Oxidation-Reduction; Peptide YY; Triglycerides; Up-Regulation; Weight Gain | 2012 |
Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy.
Topics: Adamantane; Animals; Behavior, Animal; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Dose-Response Relationship, Drug; Drinking; Eating; Glucagon-Like Peptide 1; Glucose Tolerance Test; Male; Neural Conduction; Nitriles; Pain Threshold; Peripheral Nervous System Diseases; Pyrrolidines; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging ATPase; Vildagliptin | 2012 |
Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adamantane; Animals; Blood Glucose; Body Weight; Caspase 3; Cyclic AMP; Deoxyguanosine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Eating; Gene Expression; Glomerular Basement Membrane; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Insulin; Kidney; Male; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Transforming Growth Factor beta1 | 2012 |
Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptides; Drinking; Eating; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Immunohistochemistry; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Heart Diseases; Heart Rate; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2012 |
Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
Topics: Adamantane; Albuminuria; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diastole; Drug Therapy, Combination; Fasting; Hypoglycemic Agents; Male; Nitriles; Pyrrolidines; Rats, Wistar; Systole; Telmisartan; Vildagliptin | 2014 |
Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Anti-Inflammatory Agents; Antibodies; Body Weight; Colitis; Colon; Disease Models, Animal; Enzyme Inhibitors; Glycolipids; Haptens; Immunoglobulin G; Immunosuppressive Agents; Interferon-gamma; Interleukin-18; Male; Mice; Mice, Inbred C57BL; Oxazolone; Peroxidase; Trinitrobenzenesulfonic Acid | 2004 |
Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice.
Topics: Adamantane; Animals; Body Weight; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Genotype; Glucose; Glucose Tolerance Test; Hepatocyte Nuclear Factor 1-alpha; In Vitro Techniques; Insulin; Insulin Secretion; Insulin-Secreting Cells; Intubation, Gastrointestinal; Male; Mice; Mice, Inbred CBA; Mice, Inbred Strains; Mice, Transgenic; Nitriles; Pyrrolidines; Time Factors; Vildagliptin | 2005 |
Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.
Topics: Adamantane; Animals; Body Composition; Body Weight; Candy; Energy Intake; Energy Metabolism; Glucagon-Like Peptide 1; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Pancreas; Pyrrolidines; Rats; Rats, Sprague-Dawley; Vildagliptin | 2007 |
Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Glucose Tolerance Test; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Pyrrolidines; Rosiglitazone; Thiazolidinediones; Triglycerides | 2007 |
Neonatal tactile stimulation enhances spatial working memory, prefrontal long-term potentiation, and D1 receptor activation in adult rats.
Topics: Adamantane; Age Factors; Animals; Animals, Newborn; Benzopyrans; Body Weight; Discrimination Learning; Dopamine Agonists; Environment; Female; Habituation, Psychophysiologic; Long-Term Potentiation; Male; Maternal Deprivation; Memory, Short-Term; Neuronal Plasticity; Prefrontal Cortex; Pregnancy; Rats; Rats, Wistar; Receptors, Dopamine D1; Space Perception; Touch | 2008 |
Comparison between two radiation protective substances in irradiated mice. Effect on splenic haemopoiesis.
Topics: Acetamides; Adamantane; Animals; Body Weight; Cysteamine; Hematopoiesis; Hemorrhage; Male; Mice; Mice, Inbred CBA; Organ Size; Radiation-Protective Agents; Spleen; Splenectomy; Thioacetamide | 1981 |
Effect of small-particle aerosols of rimantadine and ribavirin on pathophysiologic changes associated with A/NJ influenza in mice.
Topics: Adamantane; Aerosols; Animals; Antiviral Agents; Body Weight; Bridged-Ring Compounds; Female; Influenza A virus; Lung; Mice; Organ Size; Orthomyxoviridae Infections; Oxygen; Ribavirin; Ribonucleosides; Time Factors | 1978 |
Irradiation of mice pre-treated with radiation protective substances. A pathologic and haematologic investigation.
Topics: Acetamides; Adamantane; Administration, Oral; Animals; Body Weight; Bridged-Ring Compounds; Cysteamine; Drug Evaluation, Preclinical; Hemorrhage; Lethal Dose 50; Male; Mice; Mice, Inbred CBA; Organ Size; Radiation Injuries, Experimental; Radiation-Protective Agents; Thioacetamide | 1978 |